AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KJUN 93 min read$COCP

Cocrystal Pharma, Inc. (COCP): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Cocrystal Pharma, Inc. (COCP) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001412486 0001412486 2026-06-03 2026-06-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Repor

Original reporting
SEC EDGAR 8-K
Published Jun 9, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 9, 2026, 11:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$COCP
Neutral
medium confidence
Mentioned
$COCP
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$COCPNeutralLow
01

Why it matters

The disclosure provides concrete incentive structure (salary, bonus, option strike at $1.05, and acceleration triggers) that may influence expectations for execution and potential M&A/strategic actions, but it does not provide new operating metrics.

02

Market read

Traders may reassess COCP’s governance/execution outlook due to the CEO transition, but the filing lacks pipeline or financial catalysts.

03

What to watch

Investors may focus on whether the incoming CEO’s prior GI-focused background translates to Cocrystal’s current development priorities, but the filing does not specify strategy changes.

Relevance 6/10Novelty 6/10Timing: effective immediately (CEO appointment dated June 3, 2026; filed June 9, 2026)

Background

The 8-K (Item 5.02) reports a CEO appointment and related compensatory arrangements, replacing the company’s co-CEOs.

Company-level read

Ticker impact

$COCPNeutralMedium confidence
Context

Cocrystal Pharma appointed James Sapirstein as CEO and disclosed his base salary, bonus, and 10-year option grants with vesting/acceleration terms.

Expected impact

Likely modest, sentiment-neutral reaction unless investors view the CEO change as a clear strategic inflection.

Evidence & confidence

The filing is a primary disclosure (8-K Item 5.02) but it does not include clinical/product updates or financial guidance; impact is mainly governance/expectations rather than fundamentals.

Market effects

Sector

Biopharma governance changes can affect perceived pipeline execution quality, but no sector-wide regulatory/clinical catalyst is disclosed here.

Regional

No specific regional market linkage beyond US-listed small-cap biotech sentiment.

Global

No direct global operational or partnership update is provided.

Counterpoint

What could challenge this read

Equity compensation and vesting acceleration are standard; without pipeline/clinical milestones, the market may discount the CEO change as non-informative.

Key entities

  • issuer
    Cocrystal Pharma, Inc.

    Nasdaq-listed biopharmaceutical company filing the 8-K regarding CEO appointment and compensation.

  • executive
    James Sapirstein

    Appointed Chief Executive Officer effective immediately; receives base salary, performance bonus, and option grants with vesting/acceleration terms.

  • executive
    Sam Lee

    Former co-CEO; continues as President and Chief Scientific Officer.

  • executive
    James Martin

    Former co-CEO; continues as Chief Financial Officer and signs the filing.

Read at source← All news

Related articles

OCT 9
$COCPMedAI 8/10

H.C. Wainwright reiterates Cocrystal Pharma stock rating at buy

H.C. Wainwright reiterated a Buy rating and $6.00 price target for Cocrystal Pharma (COCP), citing progress in its norovirus drug trial. The stock is up 15% premarket. COCP's Phase 1b study for CDI-988 is ongoing, with primary endpoints focused on efficacy against norovirus. Analysts have varying price targets, ranging from $8 to $10. COCP also announced a new board member, Carol L. Brosgart, effective August 12, 2026.

investing.com1 min
OCT 16
$ASSTHigh

A 15% annual dividend accrues on $100 per share; payment depends on Strive's board declaring it.

Strive, Inc. (Nasdaq: ASST) priced its IPO of 7M shares, estimating gross proceeds of $700M. The company offers a 15% annual dividend on $100 per share, payable at the board's discretion. Strive focuses on structured finance and Bitcoin as a hurdle rate for capital deployment. Barclays and Cantor are joint book-running managers. The offering is pursuant to an SEC-registered prospectus.

stocktitan.net1 min
OCT 16
$XRPNHigh

XRP In Spotlight As Ripple CEO Brad Garlinghouse Reveals Bold Move At Evernorth Nasdaq Debut

Ripple CEO Brad Garlinghouse highlighted new XRP opportunities as Evernorth Holdings (XRPN) debuted on Nasdaq. Evernorth, backed by Ripple, aims to offer investors exposure to XRP through various strategies, including yield-generating products. The company holds 473 million XRP and raised $300 million in cash proceeds. Garlinghouse emphasized Ripple's ecosystem investments and multi-chain approach.

coingape.com2 min
OCT 15
$JPMMed

JPMorgan, Goldman Boost Yield on Volta AI Loan to Lure Investors

JPMorgan and Goldman Sachs increased the yield and improved terms on a $5 billion loan for AI cloud startup Volta Infrastructure, selling it at 6.5% above benchmark rates and 95 cents on the dollar. The loan, used to finance a Norway data center, includes investor protections and variable interest rates based on future credit ratings. The deal faced pushback from CLO managers due to its unrated status and market volatility.

finance.yahoo.com2 min
OCT 15
$IPMed

International Paper Evaluating Unsolicited Bidders for Its EMEA Packaging Business

International Paper (IP) is evaluating unsolicited bids for its EMEA Packaging Business, which operates in 30 countries. The company had previously planned to spin off this business, listing it on the London and New York stock exchanges. IP is now considering a potential sale alongside the spin-off, but no decision has been made. The EMEA Packaging Business includes both legacy DS Smith and IP assets.

paperage.com2 min